MXPA05012696A - Formulaciones de agentes antiinflamatorios no esteroides para tratar angiogenesis ocular patologica. - Google Patents

Formulaciones de agentes antiinflamatorios no esteroides para tratar angiogenesis ocular patologica.

Info

Publication number
MXPA05012696A
MXPA05012696A MXPA05012696A MXPA05012696A MXPA05012696A MX PA05012696 A MXPA05012696 A MX PA05012696A MX PA05012696 A MXPA05012696 A MX PA05012696A MX PA05012696 A MXPA05012696 A MX PA05012696A MX PA05012696 A MXPA05012696 A MX PA05012696A
Authority
MX
Mexico
Prior art keywords
formulations
inflammatory agents
steroidal anti
ocular angiogenesis
pathologic ocular
Prior art date
Application number
MXPA05012696A
Other languages
English (en)
Inventor
David P Bingaman
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of MXPA05012696A publication Critical patent/MXPA05012696A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen metodos para el uso de NSAIs en combinacion con acetato de anecortavo para prevenir y tratar angiogenesis ocular patologica y edema asociado, edema retina. PPDR o NPDR.
MXPA05012696A 2003-06-13 2004-06-14 Formulaciones de agentes antiinflamatorios no esteroides para tratar angiogenesis ocular patologica. MXPA05012696A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47825203P 2003-06-13 2003-06-13
US47822703P 2003-06-13 2003-06-13
PCT/US2004/018792 WO2004112772A1 (en) 2003-06-13 2004-06-14 Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis

Publications (1)

Publication Number Publication Date
MXPA05012696A true MXPA05012696A (es) 2006-02-22

Family

ID=33544369

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05012696A MXPA05012696A (es) 2003-06-13 2004-06-14 Formulaciones de agentes antiinflamatorios no esteroides para tratar angiogenesis ocular patologica.

Country Status (10)

Country Link
US (2) US20070043006A1 (es)
EP (1) EP1633339A4 (es)
JP (1) JP2007500250A (es)
KR (1) KR20060019579A (es)
AU (1) AU2004249167A1 (es)
BR (1) BRPI0411427A (es)
CA (1) CA2527121A1 (es)
MX (1) MXPA05012696A (es)
RU (1) RU2006101150A (es)
WO (1) WO2004112772A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004249256A1 (en) * 2003-06-20 2004-12-29 Alcon, Inc. Treatment of AMD with combination of ingredients
TW200812575A (en) * 2006-04-28 2008-03-16 Alcon Inc Formulations containing amide derivatives of carboxylic acid NSAIDs for topical administration to the eye
CA3014633C (en) 2007-10-08 2022-05-17 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors
ES2537385T3 (es) * 2009-06-09 2015-06-08 Aurinia Pharmaceuticals Inc. Sistemas de suministro tópico para uso oftálmico
WO2014207769A1 (en) 2013-06-27 2014-12-31 Mylan Laboratories Ltd Process for the preparation of nepafenac
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975537A (en) * 1985-10-23 1990-12-04 The Upjohn Company Δ9(11) -angiostatic steroids
US4771042A (en) * 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
CA1331559C (en) * 1986-04-21 1994-08-23 Jon Joseph Kabara Antimicrobial preservative compositions and methods
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
CA1325382C (en) * 1988-01-27 1993-12-21 Takahiro Ogawa Locally administrable therapeutic composition for inflammatory disease
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
DK0533703T3 (da) * 1990-06-11 2000-08-14 Alcon Lab Inc Anvendelse af steroider til hæmning af angiogenese
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5475034A (en) * 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
WO1997041867A1 (en) * 1996-05-09 1997-11-13 Alcon Laboratories, Inc. Use of steroid compounds to prevent non-cancerous tissue growth
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
JP4837861B2 (ja) * 1999-10-21 2011-12-14 アルコン，インコーポレイティド ドラッグデリバリ製剤
CA2383572C (en) * 1999-10-21 2007-12-11 Alcon Universal Ltd. Sub-tenon drug delivery
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
AR030346A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
US6646003B2 (en) * 2001-04-02 2003-11-11 Alcon, Inc. Method of treating ocular inflammatory and angiogenesis-related disorders of the posterior segment of the eye using an amide derivative of flurbiprofen or ketorolac

Also Published As

Publication number Publication date
KR20060019579A (ko) 2006-03-03
EP1633339A1 (en) 2006-03-15
AU2004249167A1 (en) 2004-12-29
US20070043006A1 (en) 2007-02-22
US20040259765A1 (en) 2004-12-23
RU2006101150A (ru) 2006-06-10
JP2007500250A (ja) 2007-01-11
BRPI0411427A (pt) 2006-07-25
EP1633339A4 (en) 2009-06-03
WO2004112772A1 (en) 2004-12-29
CA2527121A1 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
ATE538103T1 (de) Chinazolinonverbindungen als antikrebsmittel
GB9807639D0 (en) Anti-inflammatory agents
WO2005049000A3 (en) Treatment of phenylketonurias with bh4
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
WO2002043652A3 (en) Anti-proliferative drugs
EP2286839A3 (en) Treatment of obesity and related diseases
TW200509896A (en) Analeptic and drug combinations
MXPA05008561A (es) Uso de esteroides para tratar personas que sufren de trastornos oculares.
WO2002067971A3 (en) Use of endostatin in the treatment of ocular neovascularization
WO2005013911A3 (en) Protective and therapeutic uses for tocotrienols
MXPA05012696A (es) Formulaciones de agentes antiinflamatorios no esteroides para tratar angiogenesis ocular patologica.
TW200507858A (en) Formulations of glucocorticoids to treat pathologic ocular angiogenesis
DK1244438T3 (da) Anvendelse af beta-adrenoceptorantagonister til fremstilling af et medikament til behandling af sygdomme i den ydre nethinde
MX2010004314A (es) Compuestos para inhibir la actividad de quinesina de la proteina quinesina del huso.
MX2010004313A (es) Compuestos para inhibir la actividad de quinesina de la proteina de quinesina del huso.
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
BR0314364A (pt) Uso de inibidores de pde iv para tratar angiogênese
MY136408A (en) Active substance combinations and therapies for treating abuse of alcohol
TW200635580A (en) Methods of treatment and prevention

Legal Events

Date Code Title Description
FA Abandonment or withdrawal